BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:8M2D readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of 8M2D\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07568041-752@assetmemo.bio
DTSTAMP:20261121T005235Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:8M2D: Phase 1 readout est. (NCT07568041)
DESCRIPTION:8M2D\, phase 1\, Alzheimer's Disease.\nStudy: Phase 1 Study to 
 Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheim
 er's Patients\nEstimated primary completion: September 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/8m2d#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07568041
URL:https://assetmemo.bio/drug/8m2d#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
